MEDICAL IP completes approval for medical device grade 3 by the Ministry of Food and Drug Safety for AI pneumonia analysis SW

▶ Proof of clinical safety and efficacy of ‘MEDIP Pneumovid’

▶ To advance AI technology, medical data from seven countries, including Europe and Asia, was used.

MEDICAL IP obtained a medical device grade 3 approval for AI pneumonia analysis software 'MEDIP Pneumovid' from the Ministry of Food and Drug Safety. This product is software that can 'quantify' the lesions caused by pneumonia in the patient's CT by ratio and weight.

MEDICAL IP used data from COVID-19 patients from around the world, including Korea, China, Japan, Singapore, Spain, Italy, and the Netherlands, for AI deep learning. Through this, the AI's ability to detect pneumonia lesions was maximized and its effectiveness in the global market was increased.

Medical staff can use this product to quickly judge a patient's condition based on objective numbers. Based on this, by distributing limited medical resources to the right place, it will be possible to effectively respond to the outbreak of new infectious diseases as well as COVID-19.